

In the Specification:

Please amend the specification as shown:

Please delete the paragraphs on page 13, line 1 to page 15, line 23 and replace them with the following paragraphs:

Figure 15. Human ICAM-4 peptide inhibitions of HEL cell binding to human ICAM-4Fc. x-axis: binding of HEL cells in the presence of assay buffer, defined peptides or EDTA, y-axis: percentage of input cells bound. a -p shows binding to human ICAM-4Fc. a, assay buffer, b, assay buffer plus 2mM EDTA c svpFWVrms peptide (SEQ ID NO: 9), d, tRwATSRit peptide (SEQ ID NO: 10), e, aWssLahcl peptide (SEQ ID NO: 11), f, rqgktrgp peptide (SEQ ID NO: 13), g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10), h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11), i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11), j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgktrgp peptide (SEQ ID NO: 13), k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13), l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13), n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11). Human ICAM-4Fc was coated at a concentration of 2.5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays

Figure 16. Human ICAM-4 peptide inhibitions of HEL cell binding to human ICAM-4Fc. x-axis: binding of HEL cells in the presence of assay buffer, defined peptides or EDTA, y-axis: input cells bound expressed as a percentage of binding to human ICAM-4Fc in the absence of peptides. a, assay buffer; b, assay buffer plus 2mM EDTA (26%); c, svpFWVrms peptide (SEQ ID NO: 9) (64%); d, tRwATSRit peptide (SEQ ID NO: 10) (58%); e, aWssLahcl peptide (SEQ ID NO: 11) (50%); f, rqgktrgp peptide (SEQ ID NO: 13) (105%); g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) (52%); h,

svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) (43%); i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (41%); j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgktrgp peptide (SEQ ID NO: 13) (59%); k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13) (55%); l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13) (46%); m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (**SEQ ID NO: 13**) (49%); n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13) (42%); o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13) (40%); p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (42%). Human ICAM-4Fc was coated at a concentration of 2.5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays.

Figure 17. Human ICAM-4 peptide inhibitions of HT1080 cell binding to human ICAM-4Fc. x-axis: binding of HT1080 cells in the presence of assay buffer, defined peptides or EDTA, y-axis: percentage of input cells bound. a -p shows binding to human ICAM-4Fc. a, assay buffer, b, assay buffer plus 2mM EDTA c svpFWVrms peptide (SEQ ID NO: 9), d, tRwATSRit peptide (SEQ ID NO: 10), e, aWssLahcl peptide (SEQ ID NO: 11), f, rqgktrgp peptide (SEQ ID NO: 13), g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10), h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11), i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11), j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgktrgp peptide (SEQ ID NO: 13), k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13), l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (**SEQ ID NO: 13**), n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11). Human ICAM-4Fc was coated at a concentration of 5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays.

Figure 18. Human ICAM-4 peptide inhibitions of HT1080 cell binding to human ICAM-4Fc. x-axis: binding of HT1080 cells in the presence of assay buffer, defined peptides or EDTA, y-axis: input cells bound expressed as a percentage of binding to human ICAM-4Fc in the absence of peptides. a, assay buffer; b, assay buffer plus 2mM EDTA (10%); c, svpFWVrms peptide (SEQ ID NO: 9) (41%); d, tRwATSRit peptide (SEQ ID NO: 10) (42%); e, aWssLahcl peptide (SEQ ID NO: 11) (71%); f, rqgktrgp peptide (SEQ ID NO: 13) (96%); g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) (46%); h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) (52%); i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (50%); j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgktrgp peptide (SEQ ID NO: 13) (40%); k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13) (39%); l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13) (64%); m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13) (39%); n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13) (50%); o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13) (48%); p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (52%). Human ICAM-4Fc was coated at a concentration of 5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays.

Please delete the paragraph on page 26, line 1 to page 27 line 34 and replace it with the following paragraph:

SEQ ID NOS: 40 and 1 – Combined nucleotide (SEQ ID NO: 40) and amino acid (SEQ ID NO: 41) sequence of mature human ICAM-4

1

A Q S P K G S P L A P S G T S V P F W V

GCGCAAAGCCCCAAGGGTAGCCCTCTCGCGCCCTCCGGGACCTCAGTGCCCTTCTGGGTG

101

20

160

21 40
 R M S P E F V A V Q P G K S V Q L N C S
 CGCATGAGCCCGGAGTTCGTGGCTGTGCAGCCGGGGAAGTCAGTGCAGCTCAATTGCAGC
 161 220

41 60
 N S C P Q P Q N S S L R T P L R Q G K T
 AACAGCTGTCCCCAGCCGCAGAATTCCAGCCTCCGCACCCCGCTGCGGCAAGGCAAGACG
 221 280

61 80
 L R G P G W V S Y Q L L D V R A W S S L
 CTCAGAGGGCCGGGTGGGTGTCTTACCAGCTGCTCGACGTGAGGGCCTTGGAGCTCCCTC
 281 340

81 100
 A H C L V T C A G K T R W A T S R I T A
 GCGCACTGCCTCGTGACCTGCGCAGGAAAAACACGCTGGGCCACCTCCAGGATCACCGCC
 341 400

101 120
 Y K P P H S V I L E P P V L K G R K Y T
 TACAAACCGCCCCACAGCGTGATTTTGGAGCCTCCGGTCTTAAAGGGCAGGAAATACACT
 401 460

121 140
 L R C H V T Q V F P V G Y L V V T L R H
 TTGCGCTGCCACGTGACGCAGGTGTTCCCGGTGGGCTACTTGGTGGTGACCCTGAGGCAT
 461 520

141 160
 G S R V I Y S E S L E R F T G L D L A N
 GGAAGCCGGGTCATCTATTCCGAAAGCCTGGAGCGCTTCACCGGCCTGGATCTGGCCAAC
 521 580

161 180

V T L T Y E F A A G P R D F W Q P V I C
 GTG**AC**TTGACCTACGAGTTTGCTGCTGGACCCCGCGACTTCTGGCAGCCCGTGATCTGC
 581 640

181 200
 H A R L N L D G L V V R N S S A P I T L
 CACGCGCGCCTCAATCTCGACGGCCTGGTGGTCCGCAACAGCTCGGCACCCATTACACTG
 641 700

201 220
 M L A W S P A P T A L A S G S I A A L V
 ATGCTCGCTTGGAGCCCGCGCCACAGCTTTGGCCTCCGGTTCATCGCTGCCCTTGTA
 701 760

221 240
 G I L L T V G A A Y L C K C L A M K S Q
 GGGATCCTCCTCACTGTGGGCGCTGCGTACCTATGCAAGTGCCTAGCTATGAAGTCCCAG
 761 820

241
 A
 GCG
 821-823

Underlined and in bold are the mutated residues which comprise the footprint (F18, W19, V20, R92, A94, T95, S96, R97, T91, R52, E151, T154, W93, L80, W77).

In bold and in italics are the "super-adhesive" residues involved in the N-glycosylation site (N160 and T162).

W66 and K118 are shown in bold alone.